INTEGRATED CANCER CARE · VANCOUVER, BC, CANADA
Monday–Friday 9–5   |   604-428-1991
Research library

Hyperthermia Combined with Chemotherapy – Biological Rationale, Clinical Application, and Treatment Results

Research archive · This publication is preserved from the LEMMO Cancer Care library. Findings are specific to the study design and population and may not reflect current clinical practice.

Hyperthermia Combined with Chemotherapy – Biological Rationale, Clinical Application, and Treatment Results

R. Issels

GSF – Forschungszentrum für Umwelt und Gesundheit, Institut für Molekulare Immunologie und Klinikum Großhadern, Medizinische Klinik III

Summary
There is substantial evidence from preclinical data that the antitumor cytotoxicity of selected chemotherapeutic agents either alone or combined with radiation can be enhanced by appropriate heat exposure (40–44 °C) of cells or tumor tissues. Based upon these results the integration of hyperthermia as an additional treatment modality, given simultaneously with systemic chemotherapy or in combination with radiochemotherapy, is currently tested at the clinic. Regional hyperthermia combined with chemotherapy or radiochemotherapy showed impressive results (phase II studies) at clinical relevant temperatures in locally advanced tumors of
different entities in terms of objective response rate, local tumor control and relapse-free survival. Clinical protocols of well-designed phase III trials on combined treatment modalities integrating hyperthermia are rather limited but for some tumors confirm its clinical benefit. In general, the clinical approach to use hyperthermia has gained much more interest within in the field of medical oncology. One of the major reason is the substantial technical improvements made with the available commercial equipment for local or regional heating, especially in case of deep-seated lesions or systemic heating. Further testing of the potential of hyperthermia combined with chemotherapy or radiochemotherapy in prospective randomized trials are warranted. At this time, hyperthermia as an adjunct to conventional treatment strategies is recommended in the setting of clinical protocols. The results of prospective trials should answer the question for which types of local advanced or metastatic tumors hyperthermia becomes standard as part of a multimodal treatment strategy.

Download “General Hyperthermia With Chemotherapy Review 1999”

LEMMO Integrated Cancer Care
We’re here to help

A conversation can
be a beginning.

Have a question about our care or becoming a patient? Our team can explain your first visit and help you take the next step.

Let’s talk about your next step

Send us a message

For appointments and general enquiries. Leave us a message and our team will be in touch.

Call our team
604-428-1991
Email us
info@lemmo.com
Visit our clinic
Suite 205, 3900 Hastings Street
Burnaby, BC V5C 6C1
Office hours
Monday–Friday
9:00 am–5:00 pm
By appointment

Find us in Burnaby

Directions